

S/N 10/014,335

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan R. Fritzberg et al.

Examiner: Dameron L. Jones

Serial No.: 10/014,335

Group Art Unit: 1616

Filed: December 11, 2001

Docket: 295.044US1

Title: HIGH DOSE RADIONUCLIDE COMPLEXES FOR BONE MARROW SUPPRESSION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

RECEIVED

NOV 21 2003

TECH CENTER 1600/2300

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. § 1.97(c)(2), Applicants hereby authorize the Commissioner to charge the fee of \$180.00, as set forth in 37 C.F.R. §1.17(p), and any additional fees deemed necessary, to Deposit Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
ALAN R. FRITZBERG ET AL.
By their Representatives,

11/19/2003 MMEKONEN 00000001 190743 10014335

01 FC:1806 180.00 DA

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date November 12, 2003

By [Signature]
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 12th day of November 2003.

Name

Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014,335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1616
Examiner Name	Jones, Dameron

RECEIVED
NOV 21 2003
TECH CENTER 1600/2900

Sheet 1 of 1

Attorney Docket No: 295.044US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	3,974,268	08/10/1976	Subramanian et al.	424	1	05/30/1975
	5,089,249	02/18/1992	Fritzberg et al.	424	1.1	06/16/1988
	5,202,109	04/13/1993	Fritzberg et al.	424	1.1	01/31/1991

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date				
	EP 0 455 380 ✓	11/06/1991				
	WO 01/91806 ✓	12/06/2001				
	WO 02/062398 ✓	08/15/2002				
	WO 93/25240 ✓	12/23/1993				

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CLEYNHENS et al., ^{99m} Tc-EC-AMDP, a Bone Agent with Rapid Clearance from Soft Tissue", <u>Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine</u> , 5, 605-609 (1999). ✓
	COHEN et al., "Bisphosphonates and Tetracycline: Experimental Models for Their Evaluation in Calcium-Related Disorders", <u>Pharmaceutical Research</u> , 15, 606-613 (1998). ✓
	EISENHUT et al., "The Influence of Substituents in ^{99m} Tc-Benzylidenediphosphonate Complexes on their Organ Distribution in Rats", <u>Nuklearmedizin</u> , 23, 119-122 (1984). ✓
	FUJISAKI et al., "Physicochemical Characterization of Bisphosphonic Carboxyfluorescein for Osteotropic Drug Delivery", <u>J Pharm Pharmacol.</u> , 48, 798-800 (1996). ✓
	JARVIS et al., "Characterization of the Bisphosphonate Recognition Site on Hydroxyapatite Using Radioligand Binding Techniques with [¹⁴ C]Citric Acid", <u>Calcif Tissue Int.</u> , 52, 372-377 (1993). ✓
	LARSEN et al., "Preliminary Evaluation of a New Radiolabelled Bisphosphonate", <u>Journal of Labelled Compounds and Radiopharmaceuticals</u> , XLI, 823-830 (1998). ✓

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached